Further studies are required to measure PD–L1 and PD–L2 expression on CD14+ cells in patients with HCC prior to treatment with anti-PD-1 antibody and to confirm the effectiveness of anti-PD-1 antibody on such patients. This evidence concerns the gene PDCD1 and hepatocellular carcinoma.